Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1951 2
1952 6
1953 9
1954 6
1955 2
1956 4
1957 1
1958 4
1959 3
1964 1
1965 5
1966 29
1967 43
1968 23
1969 34
1970 36
1971 29
1972 40
1973 33
1974 23
1975 13
1976 21
1977 16
1978 17
1979 14
1980 13
1981 12
1982 11
1983 8
1984 17
1985 14
1986 13
1987 14
1988 21
1989 30
1990 19
1991 16
1992 38
1993 36
1994 27
1995 43
1996 33
1997 31
1998 36
1999 36
2000 25
2001 39
2002 46
2003 49
2004 38
2005 42
2006 49
2007 47
2008 56
2009 50
2010 71
2011 82
2012 188
2013 384
2014 398
2015 348
2016 335
2017 351
2018 301
2019 307
2020 352
2021 311
2022 366
2023 285
2024 306
2025 261
2026 69

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,397 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Hochhaus A, et al. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. N Engl J Med. 2024. PMID: 38820078 Clinical Trial.
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Peña AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M; CheckMate 9DW investigators. Yau T, et al. Lancet. 2025 May 24;405(10492):1851-1864. doi: 10.1016/S0140-6736(25)00403-9. Epub 2025 May 8. Lancet. 2025. PMID: 40349714 Free article. Clinical Trial.
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Van Dao T, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Paskow MJ, Ran D, Xynos I, Kurland JF, Negro A, Abou-Alfa GK. Rimassa L, et al. J Hepatol. 2025 Oct;83(4):899-908. doi: 10.1016/j.jhep.2025.03.033. Epub 2025 Apr 11. J Hepatol. 2025. PMID: 40222621 Free article. Clinical Trial.
Skincare ingredients recommended by cosmetic dermatologists: A Delphi consensus study.
Alvarez GV, Kang BY, Richmond AM, Hoss E, Sulewski R, Minkis K, Rozenberg SS, Antonovich D, Boucher A, Bernstein EF, Bertucci V, Chapas AM, Cohen JL, Council ML, Dover JS, Geronemus R, Given KML, Goldbach HS, Goldman MP, Hooper D, Kaufman J, Munavalli G, Pacheco TR, Rossi AM, Wilson S, Alam M. Alvarez GV, et al. J Am Acad Dermatol. 2025 Dec;93(6):1509-1525. doi: 10.1016/j.jaad.2025.04.021. Epub 2025 Apr 14. J Am Acad Dermatol. 2025. PMID: 40233838
Management of follicular thyroid carcinoma.
Yamazaki H, Sugino K, Katoh R, Matsuzu K, Kitagawa W, Nagahama M, Saito A, Ito K. Yamazaki H, et al. Eur Thyroid J. 2024 Oct 16;13(5):e240146. doi: 10.1530/ETJ-24-0146. Print 2024 Oct 1. Eur Thyroid J. 2024. PMID: 39419099 Free PMC article. Review.
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.
Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, Kachnic LA, Gillin MT, Hong TS, Craig TD, Williams TM, Hosni A, Chen E, Noonan AM, Koay EJ, Sinha R, Lock MI, Ohri N, Dorth JA, Delouya G, Swaminath A, Moughan J, Crane CH. Dawson LA, et al. JAMA Oncol. 2025 Feb 1;11(2):136-144. doi: 10.1001/jamaoncol.2024.5403. JAMA Oncol. 2025. PMID: 39699905 Free PMC article. Clinical Trial.
Nicotinamide for Skin Cancer Chemoprevention.
Breglio KF, Knox KM, Hwang J, Weiss R, Maas K, Zhang S, Yao L, Madden C, Xu Y, Hartman RI, Wheless L. Breglio KF, et al. JAMA Dermatol. 2025 Nov 1;161(11):1140-1147. doi: 10.1001/jamadermatol.2025.3238. JAMA Dermatol. 2025. PMID: 40960808
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
Melero I, Yau T, Kang YK, Kim TY, Santoro A, Sangro B, Kudo M, Hou MM, Matilla A, Tovoli F, Knox J, He AR, El-Rayes B, Acosta-Rivera M, Lim HY, Soleymani S, Yao J, Neely J, Tschaika M, Hsu C, El-Khoueiry AB. Melero I, et al. Ann Oncol. 2024 Jun;35(6):537-548. doi: 10.1016/j.annonc.2024.03.005. Epub 2024 May 22. Ann Oncol. 2024. PMID: 38844309 Free article. Clinical Trial.
5,397 results